Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use

Details for Australian Patent Application No. 2004305111 (hide)

Owner Novartis Vaccines and Diagnostics, Inc.

Inventors Reinhard, Christoph; Jefferson, Ann B.; Burkoth, Timothy S.; Zuckermann, Ronald N.

Agent FB Rice

Pub. Number AU-B-2004305111

PCT Pub. Number WO2005/060697

Priority 60/530,953 19.12.03 US

Filing date 20 December 2004

Wipo publication date 7 July 2005

Acceptance publication date 28 April 2011

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

C12N 15/87 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Event Publications

13 July 2006 PCT application entered the National Phase

  PCT publication WO2005/060697 Priority application(s): WO2005/060697

20 November 2008 Alteration of Name

  The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

28 April 2011 Application Accepted

  Published as AU-B-2004305111

25 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004305120-Methods of use of probiotic Lactobacilli for companion animals

2004305087-Intravenous medication harm index system